Aug 30, 2013, 01.58 PM IST
The stock movement is on the back of news that its subsidiary Taro Pharmaceutical has entered an exclusive licensing and co-development agreement with Novabiotics for its investigational new drug.
Like this story, share it with millions of investors on M3
Sun Pharma is Nifty's top gainer as Taro inks drug pact
The stock movement is on the back of news that its subsidiary Taro Pharmaceutical has entered an exclusive licensing and co-development agreement with Novabiotics for its investigational new drug.
Like this story, share it with millions of investors on M3
Sun Pharma is Nifty's top gainer as Taro inks drug pact
The stock movement is on the back of news that its subsidiary Taro Pharmaceutical has entered an exclusive licensing and co-development agreement with Novabiotics for its investigational new drug.
Taro pharma has entered into an agreement with NovaBiotics to license and co-develop Novexatin, a topical anti-fungal drug to cure toe-nail infections.
NovaBiotics and Taro will jointly manage the study and other development activities for the drug with Taro being the lead partner of the program. The drug is currently in Phase 2 (a) and will soon enter phase 2 (b)
This is a very lucrative deal for both the companies as the drug will be able to cure infections in just 28 days whereas other drugs needed atleast 3 to 4 months and a course of one year to cure the fungal infection completely.
Action in Sun Pharmaceutical Industries
Anda sedang membaca artikel tentang
Sun Pharma is Nifty's top gainer as Taro inks drug pact
Dengan url
http://gayafashionshow.blogspot.com/2013/08/sun-pharma-is-niftys-top-gainer-as-taro.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Sun Pharma is Nifty's top gainer as Taro inks drug pact
namun jangan lupa untuk meletakkan link
Sun Pharma is Nifty's top gainer as Taro inks drug pact
sebagai sumbernya
0 komentar:
Posting Komentar